## BRO: Brown & Brown, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_20 -1.9% below STRENGTH zone (4.0-10.0%); PEG 4.41 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($76.15)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 1)

**1. Brown & Brown Inc. stock underperforms Tuesday when compared to competitors**
- Source: MarketWatch | 20251202T170300 | Somewhat-Bearish | Relevance: 100%
- Brown & Brown Inc. stock decreased by 1.65% on Tuesday, closing at $79.84, despite an overall positive trading day for the broader market. The company's stock underperformed the S&P 500 Index and Dow Jones Industrial Average, and is currently 36.47% below its 52-week high.

**2. Russell Investments Group Ltd. Has $17.16 Million Holdings in Brown & Brown, Inc. $BRO**
- Source: MarketBeat | 20251202T110514 | Somewhat-Bullish | Relevance: 100%
- Russell Investments Group Ltd. significantly reduced its stake in Brown & Brown, Inc. by 28.5% in the second quarter, now holding 154,842 shares valued at approximately $17.16 million. This reduction comes amid varied analyst ratings, with an average target price of $102.69 and several recent price target trims. Despite the institutional selling, Brown & Brown reported strong Q2 earnings, beating EPS estimates, increasing revenue by 35.4% year-over-year, and raising its quarterly dividend.

**3. Q3 Results Fail to Shift Barclaysâ€™ Equal Weight Rating on Brown & Brown (BRO)**
- Source: Insider Monkey | 20251202T080600 | Somewhat-Bullish | Relevance: 100%
- Barclays maintained its Equal Weight rating on Brown & Brown (BRO) despite the company reporting robust Q3 2025 revenues of $1.6 billion, a 35% growth year-over-year, and a 170 basis point expansion in its EBITDAC margin. The firm lowered its price target to $84 from $102. Brown & Brown also announced a 10% dividend increase, marking 32 consecutive years of growth, and an expansion of its share repurchase program to $1.5 billion.

**4. Brown & Brown Employer Health and Benefits Strategy Survey | 2026 Edition**
- Source: Brown & Brown | 20251201T190628 | Neutral | Relevance: 100%
- Brown & Brown's second annual Employer Health and Benefits Strategy Survey for 2026 highlights rising costs, evolving workforce needs, and a focus on innovation and sustainability as key shapers of the benefits landscape. The survey, which included 1,241 employers, found a shift in strategic priorities, with cost control now topping the list for both employees and employers. Attracting and retaining a healthy and engaged workforce, previously the top priority, moved to third place.

**5. Skandinaviska Enskilda Banken AB publ Has $10.97 Million Stake in Brown & Brown, Inc. $BRO**
- Source: MarketBeat | 20251201T115043 | Somewhat-Bullish | Relevance: 100%
- Skandinaviska Enskilda Banken AB publ significantly increased its stake in Brown & Brown, Inc. by 88.3%, now holding 98,935 shares valued at $10.97 million. This move follows Brown & Brown reporting strong quarterly results, beating EPS estimates, and an increase in its quarterly dividend. The company maintains an average "Hold" rating from analysts with an average target price of $102.69.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $84 | $102 | -18% |
| 2025-11-17 | Morgan Stanley | $85 | $95 | -11% |
| 2025-11-04 | Keefe, Bruyette | $79 | $92 | -14% |
| 2025-11-03 | B of A Securiti | $97 | $135 | -28% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Equal-Weight |
| 2025-11-17 | Morgan Stanley | main | Equal-Weight |
| 2025-11-04 | Keefe, Bruyette | main | Underperform |
| 2025-11-03 | B of A Securiti | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($0.00M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 10.9% (+4.8%)
- Blackrock Inc.: 6.1% (+2.2%)
- Capital World Invest: 5.1% (+81.1%)
- Principal Financial : 4.5% (+13.4%)
- State Street Corpora: 3.8% (+5.3%)

### Key Risks

1. Valuation stretched: PEG 4.4x requires aggressive growth execution.
2. Long-term trend broken: trading 22.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.41 signals overvaluation risk, limited margin of safety. Quality metrics strong (margin 19%). Revenue growth strong at 23% YoY. Analyst sentiment negative (4 target cuts vs 0 raises). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $27.6B |
| Beta | 0.81 |
| 52W Range | $76.17 - $125.68 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.41 |
| Forward P/E | 17.1 |
| Current P/E | 18.8 |
| YoY Growth | 9.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.6% to -1.9% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). Below SMA200 (0.78x), long-term trend not supportive. RSI neutral at 41. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.89% (CS: 32) | Neutral |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | 0.49 | Bullish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 0.929x | Below |
| vs SMA200 | 0.779x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $79.65
- **Stop Loss:** $76.15 (4.4% risk)
- **Target:** $83.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 271
- **Position Value:** $21,585.15
- **Portfolio %:** 21.59%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-01-26 (Est: $0.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.93 | $1.05 | +12.9% |
| 2025Q2 | $0.99 | $1.03 | +4.6% |
| 2025Q1 | $1.30 | $1.29 | -0.5% |
| 2024Q4 | $0.77 | $0.86 | +12.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*